TP53 and neuroblastoma: Neither single agent nor combination treatments showed antitumor activity in the IMR-32 xenograft tumors that contain wild-type ALK and TP53 (Figure 3A and Figure 3—source data 1), suggesting that the combined inhibition of ALK and MDM2 provides an effective treatment in TP53 wild-type neuroblastoma with ALK aberrations.